-
Uncategorized2 weeks agoSTAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
CHICAGO — Ivonescimab, a drug that combines the activity of two of the best-selling cancer medicines, reduced the risk of death in patients with squamous non-small...
-
Uncategorized2 weeks ago‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.
-
Uncategorized2 weeks ago
The ocean’s health may depend on a tiny microbe inside fish
A surprising new discovery suggests that tiny microbes living inside fish may be helping shape the chemistry of the world’s oceans. Scientists found evidence that bacteria...
-
Uncategorized2 weeks ago
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline message, detailed results from ivonescimab’s chemo-combo readout in first-line lung cancer are being picked...
-
Uncategorized2 weeks agoSTAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions...
-
Uncategorized2 weeks agoSTAT+: China competition, ‘destruction’ at FDA gives agency chance to restructure, Rick Pazdur says
CHICAGO — Rick Pazdur, the former top oncology regulator at the Food and Drug Administration, said the damage done under recent political appointees opens a chance...
-
Uncategorized2 weeks ago
In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall...
-
Uncategorized2 weeks agoSTAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
CHICAGO — The biotech company Revolution Medicines has begun sending its experimental, life-extending treatment for pancreatic cancer to physicians and their patients under an early access...
-
Uncategorized2 weeks agoSTAT+: As Ebola outbreak grows, Trump administration veers from previous government playbook
WASHINGTON — In January 2025, with the Covid-19 pandemic still top of mind, the Biden administration left behind extensive plans for how the federal bureaucracy should...
-
Uncategorized2 weeks agoSTAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions...
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
